Roy A. Whitfield
Director · NEKTAR THERAPEUTICS
Individual
- 2025
- Sep 26, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Roy A. Whitfield files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Howard W. Robin - $1.42M in NKTR purchases and sales in the last 12 months
- Jonathan Zalevsky - $974K in NKTR purchases and sales in the last 12 months
- Mark Andrew Wilson - $34K in NKTR purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Roy A. Whitfield?
Roy A. Whitfield is a corporate insider, tracked as Director of NEKTAR THERAPEUTICS (NKTR). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Roy A. Whitfield submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
